<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T16:58:18Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/61877" metadataPrefix="dim">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/61877</identifier><datestamp>2024-12-16T07:27:16Z</datestamp><setSpec>com_10324_1133</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1209</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
<dim:field mdschema="dc" element="contributor" qualifier="author" authority="da57c42cbf3e6af4" confidence="600" orcid_id="0000-0003-2612-934X">Gutiérrez Abejón, Eduardo</dim:field>
<dim:field mdschema="dc" element="contributor" qualifier="author" authority="e5c7077cb4f7d529" confidence="600" orcid_id="0000-0002-3110-692X">Herrera Gómez, Francisco Magno</dim:field>
<dim:field mdschema="dc" element="contributor" qualifier="author" authority="49d7531f-4e0b-4a06-83e6-80d4ff474f24" confidence="600" orcid_id="">Pedrosa Naudín, M. Aránzazu</dim:field>
<dim:field mdschema="dc" element="contributor" qualifier="author" authority="6336dab28037c784" confidence="600" orcid_id="">Tamayo Gómez, Eduardo</dim:field>
<dim:field mdschema="dc" element="contributor" qualifier="author" authority="8d6f2f2adc53991f" confidence="600" orcid_id="0000-0002-7566-5678">Álvarez González, Francisco Javier</dim:field>
<dim:field mdschema="dc" element="date" qualifier="accessioned">2023-10-04T11:10:25Z</dim:field>
<dim:field mdschema="dc" element="date" qualifier="available">2023-10-04T11:10:25Z</dim:field>
<dim:field mdschema="dc" element="date" qualifier="issued">2022</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="citation" lang="es">Medicina, 2022, Vol. 58, Nº. 6, 829</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="issn" lang="es">1648-9144</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="uri">https://uvadoc.uva.es/handle/10324/61877</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="doi" lang="es">10.3390/medicina58060829</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="publicationfirstpage" lang="es">829</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="publicationissue" lang="es">6</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="publicationtitle" lang="es">Medicina</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="publicationvolume" lang="es">58</dim:field>
<dim:field mdschema="dc" element="identifier" qualifier="essn" lang="es">1648-9144</dim:field>
<dim:field mdschema="dc" element="description" lang="es">Producción Científica</dim:field>
<dim:field mdschema="dc" element="description" qualifier="abstract" lang="es">Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS.</dim:field>
<dim:field mdschema="dc" element="description" qualifier="project" lang="es">Junta de Castilla y León, Gerencia Regional de Salud - (Grant GRS COVID 10/A/20)</dim:field>
<dim:field mdschema="dc" element="format" qualifier="mimetype" lang="es">application/pdf</dim:field>
<dim:field mdschema="dc" element="language" qualifier="iso" lang="es">eng</dim:field>
<dim:field mdschema="dc" element="publisher" lang="es">MDPI</dim:field>
<dim:field mdschema="dc" element="rights" qualifier="accessRights" lang="es">info:eu-repo/semantics/openAccess</dim:field>
<dim:field mdschema="dc" element="rights" qualifier="uri" lang="*">http://creativecommons.org/licenses/by/4.0/</dim:field>
<dim:field mdschema="dc" element="rights" qualifier="holder" lang="es">© 2022 The Authors</dim:field>
<dim:field mdschema="dc" element="rights" lang="*">Atribución 4.0 Internacional</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">SARS-CoV-2</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">COVID-19</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">SARS (Disease)</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Syndromes</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Clinical findings</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Pharmacotherapy</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Survival</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Supervivencia</dim:field>
<dim:field mdschema="dc" element="subject" lang="es">Virology</dim:field>
<dim:field mdschema="dc" element="subject" qualifier="unesco" lang="es">3209 Farmacología</dim:field>
<dim:field mdschema="dc" element="subject" qualifier="unesco" lang="es">32 Ciencias Médicas</dim:field>
<dim:field mdschema="dc" element="subject" qualifier="unesco" lang="es">2420 Virología</dim:field>
<dim:field mdschema="dc" element="title" lang="es">Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival</dim:field>
<dim:field mdschema="dc" element="type" lang="es">info:eu-repo/semantics/article</dim:field>
<dim:field mdschema="dc" element="type" qualifier="hasVersion" lang="es">info:eu-repo/semantics/publishedVersion</dim:field>
<dim:field mdschema="dc" element="relation" qualifier="publisherversion" lang="es">https://www.mdpi.com/1648-9144/58/6/829</dim:field>
<dim:field mdschema="dc" element="peerreviewed" lang="es">SI</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>